HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden

Abstract The genetically engineered chimeric antigen receptor T cell (CAR‐T) therapy has shown remarkable clinical efficacy in the treatment of hematological malignancies. Nonetheless, it is difficult to harvest adequate autologous T cells to manufacture potent CAR‐T cell products in patients with h...

Descripción completa

Detalles Bibliográficos

Autores principales:	Yue Huang, Qin Yu, Elaine Tan Su Yin, Guoqing Wei, Wenjun Wu, Alex H. Chang, He Huang, Yongxian Hu
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Wiley 2022-06-01
Colección:	ImmunoMedicine
Materias:	acute lymphoblastic leukemia allogeneic chimeric antigen receptor T cells central nervous system leukemia cytokine release syndrome HLA‐matched
Acceso en línea:	https://doi.org/10.1002/imed.1032
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!